Neoadjuvant chemotherapy before surgery for certain digestive neuroendocrine cancers
Part of Cancer, Digestive system clinical trials.
This study looks at whether chemotherapy given before surgery improves how long patients live without the cancer coming back. It’s aimed at people with localized, poorly differentiated digestive neuroendocrine carcinoma with a higher growth rate marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor is a digestive neuroendocrine carcinoma confirmed by pathology (biopsy/surgery), and it matches the study’s “poorly differentiated” and fast-growth criteria (Ki-67 over 20%).
- Your cancer is localized (no spread to other organs/metastasis) on scans done within 21 days before treatment starts.
- You must be able to complete the needed scans, including PET and CT, to check lymph nodes and rule out other affected areas.
- Your tumor must be operable, meaning it can be removed by surgery (resectable as decided by the surgical team).
- You are age 18 or older and can sign consent and follow the study plan.
- If you can become pregnant: you need a negative pregnancy test and must use reliable birth control during treatment and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy drugs (capecitabine and temozolomide) after surgery can help prevent pancreatic neuroendocrine tumors from coming back. You're eligible if your tumor was completely removed and shows intermediate to high risk of recurrence.
This trial tests if removing as much tumor as possible through surgery before a targeted radiation therapy (PRRT) can help people with well-differentiated neuroendocrine tumors that have spread to the liver. The goal is to see if this approach works better than radiation therapy alone.
This study tests a specific “before surgery” treatment (radiation plus chemotherapy), followed by more chemotherapy to improve outcomes in people with certain types of rectal cancer. You might be considered if your cancer is locally advanced but not spread to distant organs.
This trial is testing a new combination therapy (called AK112 plus other drugs) as the first treatment for people with advanced neuroendocrine cancer of the digestive system. It aims to see if adding this combination can help shrink tumors or slow their growth.
This trial studies treatments for young adults (ages 18-39) with cancers of the digestive system or neuroendocrine tumors. It aims to find better ways to help this age group, no matter the cancer stage or grade.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
Hear when a new Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.